Skip to main content
Equibles

LYCA · Lycia Therapeutics, Inc.

Track LYCA — free

Use LYCA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LYCA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$30.00 At close · Oct 23
Rebalance outlook locked
Market Cap
$1.56B
Shares
52.09M
Volume · Oct 23 2.29M Avg daily vol (1 sessions) 2.29M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$30.00 Open$28.55 Day$22.19–36.49 Available close range$30.00–30.00 Avg vol available · 1d2.3M Short vol27% DataOct 2026–Oct 2026

The closing range uses available history since Oct 23, 2026; less than a full year is stored.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Limited Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Limited
Market backdrop VIX 19.5 · elevated Equity put/call 0.67
Technical
price trend
Limited
Not enough data for a confident read.
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Limited
Not enough data for a confident read.

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
0 · 1 · 0
50 / 200-day cross
No cross Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
No short-interest data
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Price range unavailable — no recent comparable closes.

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LYCA
Lycia Therapeutics, Inc.
this stock
$1.56B — — — —
VRTX
Vertex Pharmaceuticals Inc
 $132.80B +15.6% +46.2% 30.5 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.88B +4.3% +20.8% 19.9 2.1%
MRNA
Moderna, Inc.
 $79.89B +578.5% +4.3% — 7.7%
CSLLY
Csl Ltd
 $66.42B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Volume
Short vol %
27%
As of
Oct 23, 2026
Short Total
View
Filings
SEC Filings
Latest
S-1/A
Filed
Oct 20, 2026
This year
2

Lycia Therapeutics, Inc. is offering 14,700,000 shares at an expected $16.00 to $18.00 per share for its initial public offering and Nasdaq listing under “LYCA.” LCA-0061 showed a mean maximum IgE reduction of 96% from baseline.

View
Exempt Offerings
Offering
$75.0M
Filed
Jun 25, 2026
View

Performance

5D 20D 120D MTD YTD
LYCA — — — — —
SPY -0.4% -1.5% +5.8% -0.4% +11.5%
vs SPY — — — — —
Key facts CIK 1806540 Visit website